Cipher Pharmaceuticals Inc.
CPHRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.50 | -0.27 | 0.01 | 0.08 |
| FCF Yield | 7.91% | 15.25% | 14.80% | 36.83% |
| EV / EBITDA | 22.69 | 5.66 | 3.56 | 1.28 |
| Quality | ||||
| ROIC | 21.41% | 22.91% | 39.87% | 21.04% |
| Gross Margin | 72.24% | 80.77% | 80.69% | 83.21% |
| Cash Conversion Ratio | 1.69 | 0.78 | 0.40 | 1.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.29% | -1.20% | -1.46% | -0.76% |
| Free Cash Flow Growth | 22.06% | 52.26% | -24.03% | 26.37% |
| Safety | ||||
| Net Debt / EBITDA | 1.92 | -3.42 | -2.38 | -1.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 128.49 |
| Efficiency | ||||
| Inventory Turnover | 1.60 | 1.36 | 1.86 | 2.23 |
| Cash Conversion Cycle | 148.44 | -58.75 | -58.67 | -276.15 |